Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD19-STAR-T Cells for R/R B-cell Non-Hodgkin's Lymphoma
NCT05631912Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Autologous CD19-STAR-T cell in B-cell non-Hodgkin lymphoma, sponsored by Chinese PLA General Hospital. Started Jun 2023; status: recruiting.
02
Drugs
Autologous CD19-STAR-T cell
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05631912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631912.